Articles From: Avanir Pharmaceuticals Announces Date of Fiscal 2014 Fourth Quarter Financial Results and Conference Call to Avery Dennison to Present at Investor Conference on December 11, 2014


ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Cancels Previously Scheduled Earnings Call investment picks
--Company Plans to Complete a New Human Factor Validation Study and Respond to the CRL in the First Half of Calendar 2015--
Sign-up for Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA investment picks
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Avanir Pharmaceuticals, Inc. NEW YORK , Dec.
Sign-up for AVANIR PHARMACEUTICALS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Avanir Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Otsuka Pharmaceutical Co., Ltd. - AVNR investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals to Participate in Two Conferences in December investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Avanir Pharmaceuticals, Inc. (“Avanir”) (NASDAQ:AVNR) concerning the sale to Otsuka Pharmaceutical Co., Ltd.
Sign-up for AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Otsuka Pharmaceutical Co., Ltd. investment picks
2014/12/4
Rigrodsky & Long, P.A.: Do you own shares of Avanir Pharmaceuticals, Inc. (NASDAQ GS: AVNR )? Did you purchase any of your shares prior to December 2, 2014?
Sign-up for AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/2
WILMINGTON, Del.
Sign-up for AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
VANCOUVER , Nov.
Sign-up for Avcorp announces 2014 Third Quarter Financial Results investment picks
NEW YORK , Dec.
Sign-up for Avenue Income Credit Strategies Fund December Monthly Dividend investment picks
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund November Monthly Dividend investment picks
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund November Monthly Dividend - Revised investment picks
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that its Board of Directors has appointed Michael P.
Sign-up for AVEO Announces Executive Transition and Corporate Restructuring investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
Sign-up for AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases investment picks
AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N.
Sign-up for AVEO Names Michael N. Needle, M.D., As Chief Medical Officer investment picks
AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
Sign-up for AVEO Oncology Reports Third Quarter 2014 Financial Results investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency’s centralized procedure.
Sign-up for AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that Michael P.
Sign-up for AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
2014/11/20
By Justin Baer Wall Street pay will rise slightly this year, though the increase will be offset at some banks by huge legal settlements agreed to this year, an industry recruiter said in a new study to be released later this month.
Sign-up for Average Wall Street pay to rise 4% this year investment picks
FXT Edge Filers and Lattus Enable High-Performance, Cost-Effective Access to Content PITTSBURGH and SAN JOSE, Calif.
Sign-up for Avere and Quantum Team to Optimize Storage for Upstream Workflows in Oil and Gas Exploration investment picks
Avery Dennison Corporation (NYSE:AVY) today announced preliminary, unaudited results for its third quarter ended September 27, 2014.
Sign-up for Avery Dennison Announces Third Quarter 2014 Results investment picks
The Board of Directors of Avery Dennison Corporation (NYSE:AVY) has declared a quarterly cash dividend of $0.35 per share.
Sign-up for Avery Dennison Declares Quarterly Dividend investment picks
Avery Dennison Corporation (NYSE:AVY) today announced that its board of directors has elected Mitchell R.
Sign-up for Avery Dennison Names Mitchell R. Butier President and Chief Operating Officer investment picks
Avery Dennison Corporation (NYSE: AVY) today announced that Dean A.
Sign-up for Avery Dennison to Present at Investor Conference on December 11, 2014 investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Avanir Pharmaceuticals Announces Date of Fiscal 2014 Fourth Quarter Financial Results and Conference Call to Avery Dennison to Present at Investor Conference on December 11, 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent